3692 — Hansoh Pharmaceutical Cashflow Statement
0.000.00%
- HK$137.97bn
- HK$113.20bn
- CNY12.26bn
- 100
- 18
- 97
- 85
Annual cashflow statement for Hansoh Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | — |
Source: | ARS | ARS | ARS | ARS | |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | fx Preliminary |
Net Income/Starting Line | 3,098 | 3,300 | 2,948 | 3,766 | — |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -135 | -254 | 78 | -684 | — |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -806 | -748 | -630 | -332 | — |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 2,390 | 2,577 | 2,741 | 3,116 | — |
Capital Expenditures | -1,428 | -460 | -273 | -220 | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -1,446 | -1,799 | -5,662 | 1,294 | — |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Sale of Intangible Assets | |||||
Change in Net Intangibles | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -2,874 | -2,259 | -5,935 | 1,074 | — |
Financing Cash Flow Items | — | — | — | -5.77 | — |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -1,036 | 3,417 | -818 | -754 | — |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2,282 | 3,655 | -4,053 | 3,314 | — |